|
Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents |
Tarride JE, Burke N, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Tarride JE, Burke N, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R. Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents. ClinicoEconomics and Outcomes Research 2012; 4(1): 287-298 Indexing Status Subject indexing assigned by CRD MeSH Adolescent; Canada; Child; Child, Preschool; Cost-Benefit Analysis; Humans; Influenza Vaccines; Influenza, Human; Quality-Adjusted Life Years; Vaccination; Vaccines, Attenuated AccessionNumber 22012040367 Date bibliographic record published 04/02/2013 |
|
|
|